• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
Have you ever wondered why some people seem naturally immune to certain bacterial infections? Or why do some recover quickly even after exposure to viruses? The answer may be a mysterious group of immune cells in our bodies called B-1a cells. For a long time, scientists have even debated whether humans actually possess these cells.
T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematologic malignancy, accounting for approximately 15% of childhood acute lymphoblastic leukemia (ALL) and 25% of adult ALL. While cure rates for pediatric patients can reach 80%, the long-term survival rate for adult patients remains below 40%. More concerningly, more than half of patients relapse after treatment or fail to respond to standard therapy, with the median overall survival for relapsed/refractory T-ALL being only approximately eight months. Current treatment options primarily rely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT). However, these treatments are associated with significant toxicity and high failure rates, necessitating an urgent need for safer and more effective targeted therapy strategies.
Have you ever wondered why certain cancers caused by the human papillomavirus (HPV) are so stubborn, even defying advanced immunotherapies? HPV-related cancers kill over 300,000 people worldwide each year, with cervical and head and neck cancers being particularly common. While HPV vaccines have been highly successful in preventing these diseases, treatment options for established HPV-positive tumors remain limited. In recent years, scientists have gradually realized that immune defection within the tumor microenvironment (TME) may be the key.
Breast cancer is one of the most common malignancies in women worldwide, with approximately 70% of cases being estrogen receptor-positive (ER+) subtypes. In recent years, CDK4/6 inhibitors (such as palbociclib) combined with endocrine therapy (such as tamoxifen) have become first-line treatment options for ER+ breast cancer, significantly prolonging progression-free survival. However, with widespread clinical application, drug resistance has become increasingly prominent, with approximately 30%-50% of patients experiencing disease progression after 2-3 years of treatment. The mechanisms of drug resistance are complex and diverse, including Rb protein loss and Cyclin E1 amplification, but the causes of resistance in a large number of cases remain unclear.
The median survival of patients with advanced pancreatic ductal adenocarcinoma (PDAC) is less than one year, highlighting the urgent need for treatment advances. Recently, a research paper titled "Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer" was published in Cell Reports Medicine, a subsidiary of Cell. The paper reported a phase 1 clinical trial evaluating the safety and efficacy of anti-MSLN CAR-T cell therapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Results showed that the CAR-T cell therapy was well tolerated but not highly effective. The research team further demonstrated in mouse studies that simultaneous knockout of both ID3 and SOX4 in these CAR-T cells improved long-term relapse-free survival.
Transplantation of gene-edited autologous hematopoietic stem cells has been shown to be a curative treatment for hematopoietic disorders, including β-thalassemia and sickle cell disease (SCD). While this approach has been successful in numerous clinical trials, eliminates the need for donor matching, and potentially prevents graft-versus-host disease (GvHD), it remains hampered by the difficulty in obtaining sufficient high-quality hematopoietic stem cells for ex vivo manipulation. Furthermore, prior to transplantation, myeloablative conditioning (typically chemotherapy) is required to eliminate the patient's own hematopoietic stem cells to create space in the bone marrow microenvironment for the gene-edited autologous hematopoietic stem cells. The complex process, high production costs, and significant side effects have severely limited clinical application and commercialization.
Acute pancreatitis (AP) is associated with high mortality and is characterized by increased acinar cell death and premature release and activation of digestive enzymes. During the acute phase, AP is accompanied by enhanced efferocytosis to clear apoptotic cells. The Anxa1 protein is crucial for efferocytosis, but its role in AP remains unclear. Recently, researchers published a study titled "Annexin A1 mRNA-loaded liposomes alleviate acute pancreatitis by suppressing the STING pathway and promoting efferocytosis in macrophages" in Nature Nanotechnology.
In recent years, scientists have made significant progress in cancer treatment, particularly in the development of inhibitors targeting the MYC gene. The MYC gene plays a key role in many aggressive cancers, with its aberrant activation closely linked to tumor growth and treatment resistance. Approximately 30% of cancer patients have abnormal MYC expression, making MYC a key target for cancer treatment. However, due to its complex structure and function, MYC has long been considered an undruggable target. Technological advances have enabled several MYC inhibitors to enter clinical trials, but their efficacy still requires further improvement. Therefore, exploring combination therapy strategies that synergize with MYC inhibitors is poised to become a hot topic in cancer research.
In recent years, scientists have gradually discovered that the development and progression of many cancers are closely linked to mutations in specific genes. Among them, abnormalities in the KRAS and MYC genes, like a cancer duo, play a key role in many cancers. Now, scientists from the University of North Carolina and other institutions have achieved a significant breakthrough. They have developed a two-in-one molecule that simultaneously targets and silences both cancer-related genes, KRAS and MYC, and precisely delivers the drug directly to tumor cells expressing these genes. This discovery not only offers new hope for treating some difficult-to-treat cancers but also provides new insights into cancer treatment.
Recently, a research team led by Aaron M. Ring of the Fred Hutchinson Cancer Research Center, Harriet M. Kluger of the Yale University School of Medicine, and Leon Furchtgott of the biotechnology company Seranova Bio published a major study in the top journal Nature.
